bullish

JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation

334 Views09 Mar 2023 08:55
The essence of JD Health's business is “pharmaceutical e-commerce” rather than “a comprehensive online healthcare platform”. Without second growth point with certainty, high valuation is unreasonable.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
x